Journal for ImmunoTherapy of Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2022-02-11 124525fem69暂无昵称

Awaiting Recommendation 是under review的意思么
投稿一周迅速变成这个状态是不是内审没通过要凉了

95 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2023-05-20 1321f2f792m 来自陕西省

修回后awaiting recommendation已经5天了，一直没变状态，有点慌。

112 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2023-02-22 osmataku 来自北京

马上就是awaiting recommendation,是不是完蛋了

60 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2024-10-09 osmataku 来自北京

awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的

6 0

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2023-03-15 1321f2f792m 来自陕西省

偏重的研究方向：乳腺癌
经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。

177 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2024-05-09 普外小王来自江苏省

偏重的研究方向：免疫治疗;肿瘤免疫
经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。

93 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2024-09-10 ms1000001725003009 来自广东省

审稿速度:3.0 | 投稿命中率:25.0
经验分享：接收了不容易啊希望好运传递

14 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2024-09-02 Reachu-Chan 来自北京

这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？

19 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2024-05-26 秦怂来自辽宁

审稿速度:3.0 | 投稿命中率:25.0
经验分享：中了一篇，审稿快

82 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2137975, encodeId=8ce6213e975bb, content=修回后awaiting recommendation已经5天了，一直没变状态，有点慌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Sat May 20 07:30:56 CST 2023, time=2023-05-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2115941, encodeId=66ab211594119, content=马上就是awaiting recommendation,是不是完蛋了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Feb 22 17:11:14 CST 2023, time=2023-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229896, encodeId=4b962229896a1, content=awaiting reviewer...不一定是送外审，这里的reviewer可以包括editor，也可能直接拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Oct 09 00:00:27 CST 2024, time=2024-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119814, encodeId=4c2a211981487, content=偏重的研究方向：乳腺癌 经验分享：已经在Reviewer selection 和Reviewer Assignment之间反复横跳1个月了，煎熬。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d842084788, createdName=1321f2f792m, createdTime=Wed Mar 15 22:55:25 CST 2023, time=2023-03-15, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2203650, encodeId=74872203650d2, content=偏重的研究方向：免疫治疗;肿瘤免疫 经验分享：记录一下,欢迎讨论:Awaiting Section Editor Handling第五天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/8f4d9a6f23b8461d87167a9eb33dbade/bcf9695792c341e78d98af66955952d2.jpg, createdBy=cf0c2504738, createdName=普外小王, createdTime=Thu May 09 12:38:54 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224975, encodeId=783022249e5c8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：接收了不容易啊希望好运传递, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Tue Sep 10 11:54:07 CST 2024, time=2024-09-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223749, encodeId=84ba2223e4907, content=这个期刊收单细胞生信+一点实验的文章吗？还是秒拒？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afdc8152364, createdName=Reachu-Chan, createdTime=Mon Sep 02 21:42:33 CST 2024, time=2024-09-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2206742, encodeId=61762206e4286, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：中了一篇，审稿快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epiaEEC2mpia2HqaDrqpprOYqGGnbSsJPp05KWCYFkfmRibUldic3DVHlKzwKJufdNjCd1f9lBOooSJuw/132, createdBy=43411975443, createdName=秦怂, createdTime=Sun May 26 21:06:12 CST 2024, time=2024-05-26, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=1226934, encodeId=54b812269342d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：临床肿瘤免疫 经验分享：2022元旦投稿 2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题 2022年5月中旬修回期限最后一个小时提交一审修回 2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题 2022-6-10二审修回 2022-6-18 Accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2HQN0tx7bEeQhg1dSQGicdJL7tOD7icU2u5HHfxxM4Gea1zc6m7bNniaS2zETp3dS2P6cAr9Ca5Q2debcyjum1fjQ/132, createdBy=5b491679614, createdName=石头3, createdTime=Fri Jun 17 00:02:33 CST 2022, time=2022-06-17, status=1, ipAttribution=)]

2022-06-17 石头3

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：临床肿瘤免疫
经验分享：2022元旦投稿
2022年3月中旬一审结果，大修，两个reviewer和editor都感兴趣，但也提了很多很多问题
2022年5月中旬修回期限最后一个小时提交一审修回
2022年6月1号二审结果，小修，两个reviewer对response很满意，reviewer 1追加了2个小问题
2022-6-10二审修回
2022-6-18 Accept！

140 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务